Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

[1]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[2]  C. Sotozono,et al.  HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.

[3]  Y. Sohn,et al.  Anthropological analysis of Koreans using HLA class II diversity among East Asians. , 2010, Tissue antigens.

[4]  C. Joshi,et al.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.

[5]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[6]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[7]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[8]  K. Tokunaga,et al.  HLA haplotypes in Koreans based on 107 families. , 2008, Tissue antigens.

[9]  T. Shiohara,et al.  HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. , 2008, Acta dermato-venereologica.

[10]  David Nolan,et al.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. , 2008, Immunity.

[11]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[12]  W. Klitz,et al.  HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. , 2007, Tissue antigens.

[13]  Yuan-Tsong Chen,et al.  Human leukocyte antigens and drug hypersensitivity , 2007, Current opinion in allergy and clinical immunology.

[14]  Yuan-Tsong Chen,et al.  Genetics of Severe Drug Hypersensitivity Reactions in Han Chinese , 2007 .

[15]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[16]  M. Pirmohamed,et al.  HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.

[17]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[18]  Munir Pirmohamed,et al.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions , 2006, The AAPS Journal.

[19]  B. Zhu,et al.  HLA-A, -B, and -DRB1 polymorphism defined by sequence-based typing of the Han population in Northern China. , 2006, Tissue antigens.

[20]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[21]  K. W. Lee,et al.  Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. , 2005, Tissue antigens.

[22]  Sang-Hyun Hwang,et al.  Distribution of HLA-A, B, C Allele and Haplotype Frequencies in Koreans , 2004 .

[23]  Martine Bagot,et al.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.

[24]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[25]  W. Pichler,et al.  Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.

[26]  M. Pirmohamed,et al.  Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. , 2003, Molecular pharmacology.

[27]  H. Inoko,et al.  Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. , 2000, Tissue antigens.

[28]  J. Y. Park,et al.  HLA-B*15 diversity in the Korean population. , 2000, Tissue antigens.

[29]  M. H. Park,et al.  HLA-A,-B,-DRB1 allele and haplotype frequencies in 510 Koreans. , 1999, Tissue antigens.

[30]  J. Leeder.  Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs , 1998, Epilepsia.

[31]  R. Stern,et al.  Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study , 1997, Neurology.

[32]  J. Muglia,et al.  Anticonvulsant hypersensitivity syndrome. , 1995, Archives of internal medicine.

[33]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[34]  J. Roujeau.  The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. , 1994, The Journal of investigative dermatology.

[35]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[36]  J. Roujeau.  Immune mechanisms in drug allergy. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[37]  H. Orr,et al.  HLA Class I , 1998 .

[38]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .